Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Beck

Showing results (1-10 of 233) with videos related to

Pageof 24
Sort By:
Current Pharmaceutical Biotechnology|January 18, 2011
Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatmentMichael Beck
IUBMB Life|December 17, 2009
Therapy for lysosomal storage disordersMichael Beck
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 25, 2006
The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry diseaseMichael Beck
Human Genetics|November 8, 2006
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapyMichael Beck
Wiener Medizinische Wochenschrift (1946)|August 18, 2010
Villa Metabolica - a center of excellence for the diagnosis and treatment of lysosomal storage disordersMichael Beck
Developmental Medicine and Child Neurology|November 2, 2017
Treatment strategies for lysosomal storage disordersMichael Beck
Wiener Klinische Wochenschrift|June 5, 2003
[Fabry disease: new clinical research--current therapeutic perspectives]Michael Beck
Expert Opinion on Investigational Drugs|May 31, 2002
Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry diseaseMichael Beck
Expert Opinion on Biological Therapy|February 25, 2009
Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safetyMichael Beck
Therapeutics and Clinical Risk Management|October 10, 2009
Alglucosidase alfa: Long term use in the treatment of patients with Pompe diseaseMichael Beck
Pageof 24

Showing results (1-10 of 233) with videos related to

Sort By:
Pageof 24
Current Pharmaceutical Biotechnology|January 18, 2011
Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatmentMichael Beck
IUBMB Life|December 17, 2009
Therapy for lysosomal storage disordersMichael Beck
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 25, 2006
The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry diseaseMichael Beck
Human Genetics|November 8, 2006
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapyMichael Beck
Wiener Medizinische Wochenschrift (1946)|August 18, 2010
Villa Metabolica - a center of excellence for the diagnosis and treatment of lysosomal storage disordersMichael Beck
Developmental Medicine and Child Neurology|November 2, 2017
Treatment strategies for lysosomal storage disordersMichael Beck
Wiener Klinische Wochenschrift|June 5, 2003
[Fabry disease: new clinical research--current therapeutic perspectives]Michael Beck
Expert Opinion on Investigational Drugs|May 31, 2002
Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry diseaseMichael Beck
Expert Opinion on Biological Therapy|February 25, 2009
Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safetyMichael Beck
Therapeutics and Clinical Risk Management|October 10, 2009
Alglucosidase alfa: Long term use in the treatment of patients with Pompe diseaseMichael Beck
Pageof 24